Tisotumab forvedotin-tftv is approved for recurrent or metastatic cervical cancer

Share This Post

October 2021: The FDA has given tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor combination, rapid approval for adult patients with recurrent or metastatic cervical cancer who are progressing on or after chemotherapy.

InnovaTV 204, an open-label, multicenter, single-arm clinical trial, was used to gain approval (NCT03438396). In 101 patients with recurrent or metastatic cervical cancer who had had no more than two prior systemic regimens in the recurrent or metastatic context, including at least one prior platinum-based chemotherapy treatment, efficacy was assessed. Sixty-nine percent of patients had previously received bevacizumab as part of a systemic treatment regimen. Tisotumab vedotin-tftv 2 mg/kg was given to patients every 3 weeks until disease progression or unacceptable toxicity.

The primary efficacy outcome measures were the confirmed objective response rate (ORR), as determined by an independent review committee (IRC) using RECIST v1.1, and response duration (DOR). With a median response time of 8.3 months, the ORR was 24 percent (95 percent CI: 15.9%, 33.3 percent) (95 percent CI: 4.2, not reached).

Hemoglobin decreased, fatigue, lymphocytes decreased, nausea, peripheral neuropathy, alopecia, epistaxis, conjunctival adverse reactions, haemorrhage, leukocytes decreased, creatinine increased, dry eye, prothrombin international normalised ratio increased, activated partial thromboplastin time prolonged, diarrhoea, and rash were the most common adverse reactions (25 percent), including laboratory abnormalities. A boxed warning for ocular toxicity is included on the product label.

The recommended dose is 2 mg/kg (up to 200 mg for patients under 100 kg) administered as a 30-minute intravenous infusion every three weeks until disease progression or intolerable toxicity.

Take second opinion on cervical cancer treatment


Send Details

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Limkato Korea’s first CAR T Cell therapy
CAR T-Cell therapy

Limkato: Korea’s first CAR T Cell therapy

South Korea is making significant strides in **CAR T cell therapy**, highlighted by the approval of **Limkato**, the first domestically developed CAR T therapy by **Curocell** in 2023. This milestone reduces reliance on foreign treatments and boosts Korea’s position in the global biotech industry. With strong government support and cutting-edge research, Korea is poised to advance CAR T therapies further, expanding applications and improving accessibility for cancer patients.

TIL therapy for melanoma in China
Melanoma

TIL therapy for melanoma in China

Tumor-Infiltrating Lymphocyte (TIL) therapy represents a promising advancement in the treatment of melanoma, particularly in cases where traditional treatments have failed. In China, the adoption of TIL therapy is gaining momentum, offering new hope to patients battling this aggressive form of skin cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟